Early chemotherapy after endoscopic retrograde cholangiopancreatography and survival in advanced pancreatic cancer with biliary obstruction
World Journal of Gastroenterology · 2027-01-14 · 33 (2)
DOI: 10.3748/wjg.122338 ↗Abstract
BACKGROUND Advanced pancreatic ductal adenocarcinoma is commonly complicated by malignant distal biliary obstruction, for which endoscopic retrograde cholangiopancreatography (ERCP)-guided drainage is used to relieve jaundice and restore treatment eligibility. However, its clinical value may depend on whether drainage enables timely transition to systemic chemotherapy. Evidence evaluating early chemotherapy after ERCP while accounting for time-related bias remains limited. AIM To evaluate whether chemotherapy initiation within 30 days after ERCP is associated with landmark overall survival (OS). METHODS This single-center retrospective cohort study included patients with unresectable locally advanced or metastatic pancreatic ductal adenocarcinoma and malignant distal biliary obstruction who underwent index ERCP-guided drainage from 2016 to 2025. A 30-day landmark design was used. Inverse probability of treatment weighting-weighted Kaplan-Meier and Cox models evaluated landmark OS. Firth logistic regression and competing-risk analyses explored factors associated with chemotherapy initiation within 30 days. RESULTS Among 63 ERCP patients, 61 entered the landmark cohort; 36 initiated chemotherapy within 30 days and 25 did not. Chemotherapy initiation within 30 days was associated with better landmark OS (hazard ratio = 0.36, 95%CI: 0.20-0.67, P = 0.001), with a 365-day restricted mean survival time difference of 120.4 days. Higher baseline bilirubin was associated with lower odds of chemotherapy initiation (odds ratio = 0.29, 95%CI: 0.09-0.74, P = 0.008). The 30-day cumulative incidence of chemotherapy initiation was 72.7% in the low-bilirubin group and 41.4% in the high-bilirubin group; persistently high bilirubin at baseline and day 7 identified the lowest-accessibility subgroup. CONCLUSION Early chemotherapy after ERCP was associated with better landmark survival. Baseline and early bilirubin dynamics may help identify patients at risk of bridging failure.
EUVIMED